Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696

Rang in Aktien #3772
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aktienkurs
$5.34
Marktkapitalisierung
$4.43B
Veränderung (1 Tag)
3.07%
Veränderung (1 Jahr)
-39.48%
Land
TW
Handel Lin BioScience, Inc. (6696)

Kategorie

Healthcare
Aktien-Split-Historie für Lin BioScience, Inc. (6696)
Die Aktie Lin BioScience, Inc. (Symbol: 6696) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 21, 2026 statt.
Eine 6696-Aktie, die vor dem Oct 21, 2026 gekauft wurde, entspricht heute 0 6696-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH